| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Opalska, Aleksandra |
| dc.contributor.author | Gardarsdottir, Helga |
| dc.contributor.author | Kwa, Marcel |
| dc.contributor.author | Wojkowska-Mach, Jadwiga |
| dc.contributor.author | Sabaté, Mònica |
| dc.contributor.author | Ballarín, Elena |
| dc.date.accessioned | 2024-10-02T08:23:50Z |
| dc.date.available | 2024-10-02T08:23:50Z |
| dc.date.issued | 2024-07 |
| dc.identifier.citation | Opalska A, Gardarsdottir H, Kwa M, Wójkowska-Mach J, Sabate M, Ballarin ME, et al. Use of antibiotics in the early COVID-19 pandemic in Poland, the Netherlands and Spain, from erraticism to (more) logic. Eur J Clin Pharmacol. 2024 Jul;80:1581-9. |
| dc.identifier.issn | 1432-1041 |
| dc.identifier.uri | https://hdl.handle.net/11351/12001 |
| dc.description | COVID-19; Hospitalization; Rational use of antibiotics |
| dc.description.abstract | Introduction
In the Spring of 2020, the world was hit with unparalleled impact by the coronavirus pandemic. Antibiotics were widely used, even without good rationale. The aim of our study was to compare the use of antibiotics in patients with confirmed COVID-19 from three hospitals across Europe (Poland, the Netherlands and Spain) between two subsequent periods in the early days of the pandemic.
Method
We analysed data (antibiotics used and variation in the use of antibiotics, patients, admission and disease-related characteristics) from 300 patients admitted in three hospitals (University Hospital in Cracow, University Medical Center in Utrecht and Vall d’Hebron University Hospital in Barcelona) with confirmed infection of SARS-CoV-2 during Q1 2020 and Q4 2020.
Results
There was ample variation in terms of patient mix and outcomes across the 3 hospitals. The majority of patients (225 out of 300) in all 3 hospitals received at least 1 antibiotic during the hospitalisation period. A minority of patients (68 out of 300) had their bacterial test results positive during their hospitalisation period. Throughout the 2 study periods, third-generation cephalosporins (ceftriaxone in 170 out of 300 patients) emerged as the most commonly used class of antibiotics. There was an apparent shift towards more rational utilisation of antibiotics, in all three hospitals.
Conclusions
Our study shows that during the early stage of COVID-19 pandemic in 2020, antibiotics were frequently used in three European teaching hospitals despite the relatively low incidence of microbiologically confirmed bacterial infections. While in the early days of the COVID-19 pandemic antibiotic prescribing was full of trial and error, we could also confirm a learning curve over time. |
| dc.language.iso | eng |
| dc.publisher | Springer |
| dc.relation.ispartofseries | European Journal of Clinical Pharmacology;80 |
| dc.rights | Attribution 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
| dc.source | Scientia |
| dc.subject | Hospitals - Ingressos i altes |
| dc.subject | Pandèmia de COVID-19, 2020- |
| dc.subject | Antibiòtics - Ús terapèutic |
| dc.subject.mesh | Coronavirus Infections |
| dc.subject.mesh | Pandemics |
| dc.subject.mesh | Anti-Bacterial Agents |
| dc.subject.mesh | /therapeutic use |
| dc.subject.mesh | Hospitalization |
| dc.title | Use of antibiotics in the early COVID-19 pandemic in Poland, the Netherlands and Spain, from erraticism to (more) logic |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1007/s00228-024-03726-1 |
| dc.subject.decs | infecciones por Coronavirus |
| dc.subject.decs | pandemias |
| dc.subject.decs | antibacterianos |
| dc.subject.decs | /uso terapéutico |
| dc.subject.decs | hospitalización |
| dc.relation.publishversion | https://doi.org/10.1007/s00228-024-03726-1 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Opalska A] Division Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands. Directorate-General for Health and Food Safety, European Commission, Brussels, Belgium. [Gardarsdottir H] Division Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands. Department of Clinical Pharmacy, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, Netherlands. [Kwa M] Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, Netherlands. [Wójkowska Mach J] Department of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Crakow, Poland. [Sabate M, Ballarin ME] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Farmacologia Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain |
| dc.identifier.pmid | 39017693 |
| dc.identifier.wos | 001270488700001 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |